Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
抗ＣＤ１９抗体とＢＣＬ－２阻害剤との組み合わせおよびその使用
Document Type and Number:
Japanese Patent JP7094950
Kind Code:
B2
Abstract:
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

More Like This:
WO/2003/059282HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
WO/2022/171192ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
WO/2005/020919METHOD OF TREATMENT AND BIOASSAY INVOLVING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS CARDIAC-DERIVED MYOCARDIAL DEPRESSANT FACTOR
Inventors:
Endel, Yang
Petropoulos, Constantine
Keremen, peter
Boxhammer, liner
Lucert, marx
Application Number:
JP2019522273A
Publication Date:
July 04, 2022
Filing Date:
October 27, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Morphosis Age
International Classes:
A61K39/395; A61K31/496; A61P35/00
Foreign References:
WO2013024097A1
WO2013024095A1
WO2015130585A1
Other References:
Seminars in Oncology,2016年04月01日,Vol. 43, No. 2, pp.280-290
Attorney, Agent or Firm:
Patent business corporation Kita Aoyama International



 
Previous Patent: Post-transcriptional chemically modified double-stranded RNA

Next Patent: Folding body accommodating device for bone defects